Winnonlin modeling software#
PKS is an enterprise data management system for secure storage and tracking of PK/PD data and analyses that is tightly integrated with Phoenix WinNonlin and earlier WinNonlin versions, as well as Pharsight's complementary software tools for PK analysis automation and reporting. The Phoenix platform has been developed to provide a collaborative environment for drug development scientists and to shorten the learning curve to more complex and impactful modeling, which ultimately supports more confident and efficient clinical development decisions."Ĭoncurrent with the release of Phoenix WinNonlin 6.0, Pharsight has also released version 4.0 of Pharsight Knowledgebase Server TM (PKS TM). "Phoenix WinNonlin version 6.0 merges the trusted algorithms from WinNonlin with new powerful data management tools and high-quality graphics to support comprehensive PK/PD analysis. "The release of Phoenix WinNonlin represents an important milestone in Pharsight's vision for software to enable model-based drug development and its utility in translational science," said Daniel Weiner, Ph.D., senior vice president and chief technology officer of Pharsight. In addition to the release of Phoenix WinNonlin 6.0, newly released Phoenix Connect TM software integrates applications built on the Phoenix platform with commonly used third-party analysis and modeling tools such as S-PLUS®, NONMEM® and SAS®, and enables data import/export with emerging industry standards such as CDISC. Phoenix WinNonlin will continue to operate with Pharsight's enterprise PK/PD data management system, Pharsight Knowledgebase Server TM (PKS TM), and can also be used independently of PKS. Phoenix WinNonlin will be backward-compatible with WinNonlin versions 4 and 5. The major features of Phoenix WinNonlin 6.0 include a new graphical user interface that makes creation and re-use of PK/PD analysis workflows seamless and intuitive, powerful native graphics and improved data management tools. Phoenix WinNonlin 6.0 is the cornerstone of Phoenix TM, Pharsight's new desktop software platform that is designed to advance model-based drug development by providing an integrated environment for data analysis, modeling and simulation. LOUIS - Pharsight, a market-leading provider of software and scientific services to improve productivity and decision-making in clinical drug development, today announced the launch of Phoenix WinNonlin, the next generation of the company's industry-standard software tool for pharmacokinetic and pharmacodynamic (PK/PD) modeling and noncompartmental analysis. Phoenix WinNonlin 6.0 Provides Enhancements to Industry-Standard PK/PD Analysis Tool, Adds New Interface and Workflow Management Engine Can you please share the demo project? I could not locate the demo project from your link above.Pharsight Launches Phoenix WinNonlin as Cornerstone of New Software Platform for Model-Based Drug Development Hi Serge: I have a similar question about modeling IV and SC together, with SC showing flip-flop kinetics. Look at it and you can see that in this example Ka is smaller than ke and the fit is for both sets together. When you do that and uncheck the sort button, you can also reset the time to zero when you give the SC dose. The assumption is that these are 2 separate sets of observation but with common PK. I also used the reset tab to washout all the influence of the IV data when I gave the SC. What I did is to give you data where the model parameters are the same across the 2 routes except that I added bioavailability for SC route. If that is the case, you cannot fit both together assuming same model parameters. Here in your example, the problem seems that all the PK parameters may be different across the 2 routes.
Winnonlin modeling how to#
Serge ĭear Aiqun I am attaching a demo project that shows you how to model both IV and SC together(you need to use the graphical feature and add an IV dose when taking as template extravascular input). I am attaching a demo project that shows you how to model both IV and SC together(you need to use the graphical feature and add an IV dose when taking as template extravascular input).
0 kommentar(er)
